Key result
In dogs with protein-losing nephropathy, clopidogrel altered platelet aggregometry from baseline for ADP but not AA, while aspirin showed no differences from baseline for either.
Why the study?
Dogs with protein-losing nephropathy receive antiplatelet drugs for thromboprophylaxis without a standardized method to measure response, and clopidogrel metabolite concentrations between healthy and affected dogs are unknown.
Does platelet aggregometry objectively evaluate response to clopidogrel or aspirin in dogs with protein-losing nephropathy?
Does platelet aggregometry objectively evaluate response to clopidogrel or aspirin in dogs with protein-losing nephropathy?
Platelet aggregometry can objectively evaluate response to clopidogrel in dogs with protein-losing nephropathy, who appear to metabolize clopidogrel similarly to healthy dogs.
No takes yet. Share an insight, caveat, or question.
May enable aggregometry-guided clopidogrel monitoring in affected dogs; leaves open clinical translation pending prospective trials.
Shropshire et al. (2020) studied Protein-losing nephropathy (PLN) (n=20). Aspirin or clopidogrel vs. Baseline / Healthy dogs was evaluated on Platelet aggregometry response (ADP and AA) and clopidogrel metabolite concentrations. In dogs with protein-losing nephropathy, clopidogrel altered platelet aggregometry from baseline for ADP but not AA, while aspirin showed no differences from baseline for either.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: